Figure 5: Immunohistochemical analysis of CDKN2A/p16 and SMAD4. | Scientific Reports

Figure 5: Immunohistochemical analysis of CDKN2A/p16 and SMAD4.

From: Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes

Figure 5

(A) Strong nuclear and cytoplasmatic staining of CDKN2A/p16 in neoplastic cells indicating the presence of an intact gene. (B) No labeling of CDKN2A/p16 in neoplastic cells indicating either a deletion, inactivating mutation, or promoter hypermethylation. (C) Nuclear SMAD4 immunolabeling of neoplastic cells indicating the presence of an intact protein. (D) Loss of SMAD4 expression in >90% of neoplastic cells indicating a deletion or inactivating mutation of the gene.

Back to article page